Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.
CStone Pharmaceuticals has dosed the first patient in a clinical trial designed to evaluate CS1001, the company’s experimental PD-L1 inhibitor, in ... Read more
An investigational cancer vaccine, MedImmune’s MEDI0457, can safely be used in combination with anti-PD-1 therapy to improve outcomes in patients with ... Read more
A recent collaboration between Affimed and Genentech, a member of the Roche group, aims to develop immunotherapies — called engager-based immunotherapies — that aim to establish a ... Read more
A newly developed method that combines sequencing with bioinformatics can help monitor the effectiveness of immunotherapy in patients being treated for cancer, ... Read more
The European Medicines Agency (EMA) has started the review process for Merck‘s application seeking approval of Keytruda (pembrolizumab) in combination with Alimta (pemetrexed) ... Read more
